No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Foster Corporation and AdvanSource Biomaterials Develop Marketing Partnership for Specialty TPU and TPU Alloy Products for Healthcare Market

Editor: What To Know

  • Foster Corporation's Distribution business, a leader in material solutions for the critical application healthcare market segment, has been appointed as the marketing partner for AdvanSource Biomaterials, a group company of Mitsubishi Chemical.
  • We are actually a customer of AdvanSource and have always been impressed with the quality of their product and their breadth of technology and elastomer solutions.
  • Foster's role will entail application development, sales, and technical support, of AdvanSource products in the North American healthcare market from its U.

Foster Corporation’s Distribution business, a leader in material solutions for the critical application healthcare market segment, has been appointed as the marketing partner for AdvanSource Biomaterials, a group company of Mitsubishi Chemical.

AdvanSource focuses on the manufacture and development of specialty thermoplastic polyurethane (TPU) products suited for specific application requirements. Foster’s role will entail application development, sales, and technical support, of AdvanSource products in the North American healthcare market from its U.S. locations in Connecticut and Nevada.

AdvanSource Biomaterials has developed, and offers for sale, an impressive line of thermoplastic polyurethane products for implantable and non-implantable healthcare applications. Their TPU technologies include polycarbonate aliphatic, polycarbonate aromatic, polyether aromatic, aliphatic ether, hydrophilic, as well as polycarbonate silicone elastomers and soft aromatic polyurethane alloys. Healthcare application segments include cardiology, orthopedics, drug delivery, endoscopy, wound care, urology, and neurology among others.

Foster Corporation knows TPU very well,” says Larry Acquarulo, President/Owner of Foster Corporation. “Our two companies have been talking about a sales/marketing relationship for a while. We are actually a customer of AdvanSource and have always been impressed with the quality of their product and their breadth of technology and elastomer solutions. Foster processes and sells materials for implantable applications which is also a market that AdvanSource participates in. This parallel interest makes this partnership a great match.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy